[go: up one dir, main page]

HU0203985D0 - Use of a pharmaceutical composition for alleviating side effect of a disease - Google Patents

Use of a pharmaceutical composition for alleviating side effect of a disease

Info

Publication number
HU0203985D0
HU0203985D0 HU0203985A HUP0203985A HU0203985D0 HU 0203985 D0 HU0203985 D0 HU 0203985D0 HU 0203985 A HU0203985 A HU 0203985A HU P0203985 A HUP0203985 A HU P0203985A HU 0203985 D0 HU0203985 D0 HU 0203985D0
Authority
HU
Hungary
Prior art keywords
disease
pharmaceutical composition
side effect
alleviating side
alleviating
Prior art date
Application number
HU0203985A
Other languages
Hungarian (hu)
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Priority to HU0203985A priority Critical patent/HUP0203985A3/en
Publication of HU0203985D0 publication Critical patent/HU0203985D0/en
Priority to AU2003278514A priority patent/AU2003278514A1/en
Priority to PCT/IB2003/005127 priority patent/WO2004045611A1/en
Publication of HUP0203985A2 publication Critical patent/HUP0203985A2/en
Publication of HUP0203985A3 publication Critical patent/HUP0203985A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0203985A 2002-11-18 2002-11-18 Use of a pharmaceutical composition for alleviating side effect HUP0203985A3 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU0203985A HUP0203985A3 (en) 2002-11-18 2002-11-18 Use of a pharmaceutical composition for alleviating side effect
AU2003278514A AU2003278514A1 (en) 2002-11-18 2003-11-07 Use of a thiazolidinedione for the reduction of side effects of chemotherapy
PCT/IB2003/005127 WO2004045611A1 (en) 2002-11-18 2003-11-07 Use of a thiazolidinedione for the reduction of side effects of chemotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0203985A HUP0203985A3 (en) 2002-11-18 2002-11-18 Use of a pharmaceutical composition for alleviating side effect

Publications (3)

Publication Number Publication Date
HU0203985D0 true HU0203985D0 (en) 2003-01-28
HUP0203985A2 HUP0203985A2 (en) 2004-07-28
HUP0203985A3 HUP0203985A3 (en) 2005-04-28

Family

ID=89980932

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203985A HUP0203985A3 (en) 2002-11-18 2002-11-18 Use of a pharmaceutical composition for alleviating side effect

Country Status (2)

Country Link
HU (1) HUP0203985A3 (en)
WO (1) WO2004045611A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc Quinoxaline derivatives as p13 kinase inhibitors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
WO2000018234A1 (en) * 1998-09-29 2000-04-06 Board Of Regents, The University Of Texas System Thiazolidenediones alone or in combination with other therapeutic agents for tumor therapy
WO2002080913A1 (en) * 2001-04-06 2002-10-17 F. Hoffmann-La Roche Ag Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth

Also Published As

Publication number Publication date
WO2004045611A1 (en) 2004-06-03
WO2004045611A8 (en) 2004-08-26
HUP0203985A2 (en) 2004-07-28
HUP0203985A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
GB2394894B (en) New use for pharmaceutical composition
GB0217225D0 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
PL377495A1 (en) Solid drug for oral use
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
GB2392618B (en) Compositions for therapeutic use
AP2004003087A0 (en) Oral dosage form for controlled drug release
HU0203985D0 (en) Use of a pharmaceutical composition for alleviating side effect of a disease
IL175556A0 (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
AU2003222571A8 (en) Novel therapeutic application for a composition
ZA200603126B (en) Pharmaceutical compositions for therapeutic use
EP1491189A4 (en) Diclofenac sodium oral pharmaceutical
IL147496A (en) Preparation of a therapeutic composition
EP1547593A4 (en) Medicinal composition
GB0226830D0 (en) Composition for use as a medicament
SI1701698T1 (en) Directly compressible pharmaceutical composition for the oral admimistration of cci-779
GB0224494D0 (en) Medicinal compounds
GB0215930D0 (en) Medicinal compounds
GB0224508D0 (en) Medicinal compounds
GB0225023D0 (en) Medicinal compounds

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished